{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:01:40Z","timestamp":1791313300124,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jchf.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T14:37:10Z","timestamp":1682519830000},"page":"1507-1517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Polypharmacy and Optimization of Guideline-Directed Medical Therapy in\u00a0Heart\u00a0Failure"],"prefix":"10.1016","volume":"11","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumitabh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Segar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shariq","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-8670","authenticated-orcid":false,"given":"Neil","family":"Keshvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Fiuzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-4569","authenticated-orcid":false,"given":"Harriette G.C.","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-8093","authenticated-orcid":false,"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2023.03.007_bib1","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.03.007_bib2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2023.03.007_bib3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jacc.2021.02.006","article-title":"Quadruple medical therapy for heart failure: medications working together to provide the best care","volume":"77","author":"Greene","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.03.007_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.03.007_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12872-019-1175-3","article-title":"Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study","volume":"19","author":"Durstenfeld","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jchf.2023.03.007_bib6","first-page":"161","article-title":"Treatment differences in medical therapy for heart failure with reduced ejection fraction between sociodemographic groups","volume":"11","author":"Witting","year":"2023","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.03.007_bib7","first-page":"1","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.03.007_bib8","first-page":"266","article-title":"Frailty, guideline-directed medical therapy, and outcomes in HFrEF: from the GUIDE-IT trial","volume":"10","author":"Khan","year":"2022","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.03.007_bib9","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/ehf2.13954","article-title":"Multimorbidity, guideline-directed medical therapies, and associated outcomes among hospitalized heart failure patients","volume":"9","author":"Takeuchi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2023.03.007_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10741-021-10135-4","article-title":"Polypharmacy definition and prevalence in heart failure: a systematic review","volume":"27","author":"Beezer","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.jchf.2023.03.007_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jchf.2023.03.007_bib12","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2019.03.467","article-title":"Deprescribing in older adults with cardiovascular disease","volume":"73","author":"Krishnaswami","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.03.007_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","article-title":"Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: a secondary analysis of a randomized clinical trial","volume":"5","author":"Fiuzat","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.03.007_bib14","first-page":"457","article-title":"Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure","volume":"2","author":"Felker","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.03.007_bib15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide\u2013guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2023.03.007_bib16","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.03.007_bib17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/ejhf.1450","article-title":"Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score","volume":"21","author":"O'Connor","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.03.007_bib18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2307\/2533118","article-title":"A\u00a0joint model for survival and longitudinal data measured with error","volume":"53","author":"Wulfsohn","year":"1997","journal-title":"Biometrics"},{"key":"10.1016\/j.jchf.2023.03.007_bib20","first-page":"1","article-title":"lmerTest package: tests in linear mixed effects models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.jchf.2023.03.007_bib21","author":"Therneau"},{"key":"10.1016\/j.jchf.2023.03.007_bib22","first-page":"1","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.jchf.2023.03.007_bib23","series-title":"Modeling survival data: extending the Cox model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.jchf.2023.03.007_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","article-title":"Polypharmacy in older adults hospitalized for heart failure","volume":"13","author":"Unlu","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.jchf.2023.03.007_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/JCN.0000000000000885","article-title":"Polypharmacy and clinical outcomes in hospitalized patients with acute decompensated heart failure","volume":"38","author":"Ozasa","year":"2023","journal-title":"J\u00a0Cardiovasc Nurs"},{"key":"10.1016\/j.jchf.2023.03.007_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008293","article-title":"Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction","volume":"14","author":"Minamisawa","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.03.007_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24285-4","article-title":"Polypharmacy and risk of mortality among patients with heart failure following hospitalization: a nested case-control study","volume":"12","author":"Perreault","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jchf.2023.03.007_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11897-022-00559-w","article-title":"Polypharmacy in older heart failure patients: a multidisciplinary approach","volume":"19","author":"Sukumar","year":"2022","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jchf.2023.03.007_bib29","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.amjmed.2021.03.038","article-title":"Polypharmacy in heart failure with reduced ejection fraction: progress, not problem","volume":"134","author":"Rao","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2023.03.007_bib30","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.amjmed.2021.05.007","article-title":"Polypharmacy in heart failure: progress but also problem","volume":"134","author":"Goyal","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2023.03.007_bib31","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.03.007_bib32","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jchf.2023.03.007_bib33","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/ejhf.2024","article-title":"Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study","volume":"22","author":"Volterrani","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.jchf.2023.03.007_bib34","first-page":"504","article-title":"Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?","volume":"7","author":"Sharma","year":"2022","journal-title":"J Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jchf.2023.03.007_bib35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1445-5994.2007.01316.x","article-title":"Potentially inappropriate prescribing among Australian veterans and war widows\/widowers","volume":"37","author":"Roughead","year":"2007","journal-title":"Intern Med J"},{"key":"10.1016\/j.jchf.2023.03.007_bib36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","article-title":"Reducing inappropriate polypharmacy: the process of deprescribing","volume":"175","author":"Scott","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jchf.2023.03.007_bib37","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.amjcard.2019.01.052","article-title":"Prescription of potentially harmful drugs in young adults with heart failure and reduced ejection fraction","volume":"123","author":"Alvarez","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2023.03.007_bib38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ageing\/aft169","article-title":"Pharmacist-led interventions to reduce unplanned admissions for older people: a systematic review and meta-analysis of randomised controlled trials","volume":"43","author":"Thomas","year":"2014","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.jchf.2023.03.007_bib39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.059661","article-title":"Should polypills be used for heart failure with reduced ejection fraction?","volume":"146","author":"Pandey","year":"2022","journal-title":"Circulation"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923001373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923001373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:04:00Z","timestamp":1761973440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177923001373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2213177923001373"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2023.03.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypharmacy and Optimization of Guideline-Directed Medical Therapy in\u00a0Heart\u00a0Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}